Daniel J. O'Connor - Jul 5, 2023 Form 4 Insider Report for Ambrx Biopharma Inc. (AMAM)

Role
President and CEO, Director
Signature
/s/ Sonja Nelson, attorney in fact for Daniel O'Connor
Stock symbol
AMAM
Transactions as of
Jul 5, 2023
Transactions value $
$0
Form type
4
Date filed
7/7/2023, 04:06 PM
Previous filing
Apr 28, 2023
Next filing
Oct 31, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMAM Stock Option (right to buy) Award $0 +1.22M $0.00 1.22M Jul 5, 2023 Ordinary Shares 1.22M $2.38 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will have an exercise price per share equal to the fair market value per ordinary share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
F2 1/6 of the Ordinary Shares subject to the option vest on January 5, 2024, and the remainder vests in ten (10) equal quarterly installments following such date.
F3 The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven Ordinary Shares of the Issuer.